poisar

Stocks · News reference

NeOnc Technologies Announces August 12 Conference Call To Present Topline Phase 2a Results From NEO100-01 Trial Of Intranasal NEO100 In IDH1-Mutant Glioma

BenzingaAug 10, 2026, 12:32 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 10, 2026, 12:32 PM
Checked
Aug 10, 2026, 12:32 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading